Actinic Keratosis Treatment Market by Drug Type (Fluorouracil, Imiquimod, Diclofenac, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-07
- Report ID: 517
- Pages: 235
-
Format:
The global actinic keratosis treatment market was valued at $1,117 million in 2018, and is projected to reach $1,558 million by 2026, registering a CAGR of 4.2% from 2019 to 2026.
Actinic keratosis (AK) is the most common precancer that forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun or indoor tanning characterized by rough, scaly patch on skin. It is most commonly found on face, lips, ears, back of your hands, forearms, scalp, or neck. Different types of treatment options available for the treatment of actinic keratosis include cryotherapy, photodynamic therapy, topical medications, and combination therapy. Drugs such as fluorouracil, imiquimod, diclofenac, ingenol mebutate, and others have been approved for the treatment of actinic keratosis.
Significant increase in prevalence of actinic keratosis, use of topical therapeutics as a first line treatment option, rise in demand for actinic keratosis therapeutics, strong presence of pipeline drugs, and rise in geriatric population are the key factors that fuel the growth of the actinic keratosis treatment market. Moreover, rise in adoption of actinic keratosis treatment medications, increase in R&D for the innovation of new products, and surge in healthcare awareness toward actinic keratosis treatment are other factors that contribute toward the growth of the market. However, availability of alternate therapies for treatment of actinic keratosis can hamper the market growth.
The actinic keratosis treatment market is segmented on the basis of drug type, type, distribution channel, and region. By drug type, the market is categorized into fluorouracil, imiquimod, diclofenac, and others. On the basis of type, the market is bifurcated into prescription and OTC. According to distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type
Fluorouracil
Imiquimod
Diclofenac
Others
By Type
Prescription
OTC
Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
3M Company
Almirall, S.A.
Bausch Health Companies Inc.
Biofrontera, Inc.
Hill Dermaceuticals, Inc.
LEO Pharma A/S
Mylan N.V
Novartis AG
Stanford Chemicals
Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Nestl S.A.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porters five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of actinic keratosis
3.4.1.2. Potential drugs present in pipeline
3.4.1.3. Increase in government expenditure on healthcare
3.4.2. Restraint
3.4.2.1. Availability of alternate treatment options
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Fluorouracil
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Imiquimod
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Diclofenac
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. OTC
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Drug stores and retail pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online providers
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: ACTINIC KERATOSIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. actinic keratosis treatment market, by drug type
7.2.2.1.2. U.S. actinic keratosis treatment market, by type
7.2.2.1.3. U.S. actinic keratosis treatment market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada actinic keratosis treatment market, by drug type
7.2.2.2.2. Canada actinic keratosis treatment market, by type
7.2.2.2.3. Canada actinic keratosis treatment market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico actinic keratosis treatment market, by drug type
7.2.2.3.2. Mexico actinic keratosis treatment market, by type
7.2.2.3.3. Mexico actinic keratosis treatment market, by distribution channel
7.2.3. North America market size and forecast, by drug type
7.2.4. North America actinic keratosis treatment market, by type
7.2.5. North America actinic keratosis treatment market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany actinic keratosis treatment market, by drug type
7.3.2.1.2. Germany actinic keratosis treatment market, by type
7.3.2.1.3. Germany actinic keratosis treatment market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France actinic keratosis treatment market, by drug type
7.3.2.2.2. France actinic keratosis treatment market, by type
7.3.2.2.3. France actinic keratosis treatment market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK actinic keratosis treatment market, by drug type
7.3.2.3.2. UK actinic keratosis treatment market, by type
7.3.2.3.3. UK actinic keratosis treatment market, by distribution channel
7.3.2.4. Italy
7.3.2.4.1. Italy actinic keratosis treatment market, by drug type
7.3.2.4.2. Italy actinic keratosis treatment market, by type
7.3.2.4.3. Italy actinic keratosis treatment market, by distribution channel
7.3.2.5. Spain
7.3.2.5.1. Spain actinic keratosis treatment market, by drug type
7.3.2.5.2. Spain actinic keratosis treatment market, by type
7.3.2.5.3. Spain actinic keratosis treatment market, by distribution channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe actinic keratosis treatment market, by drug type
7.3.2.6.2. Rest of Europe actinic keratosis treatment market, by type
7.3.2.6.3. Rest of Europe actinic keratosis treatment market, by distribution channel
7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe actinic keratosis treatment market, by type
7.3.5. Europe actinic keratosis treatment market, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan actinic keratosis treatment market, by drug type
7.4.2.1.2. Japan actinic keratosis treatment market, by type
7.4.2.1.3. Japan actinic keratosis treatment market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China actinic keratosis treatment market, by drug type
7.4.2.2.2. China actinic keratosis treatment market, by type
7.4.2.2.3. China actinic keratosis treatment market, by distribution channel
7.4.2.3. Australia
7.4.2.3.1. Australia actinic keratosis treatment market, by drug type
7.4.2.3.2. Australia actinic keratosis treatment market, by type
7.4.2.3.3. Australia actinic keratosis treatment market, by distribution channel
7.4.2.4. Rest of Asia-Pacific
7.4.2.4.1. Rest of Asia-Pacific actinic keratosis treatment market, by drug type
7.4.2.4.2. Rest of Asia-Pacific actinic keratosis treatment market, by type
7.4.2.4.3. Rest of Asia-Pacific actinic keratosis treatment market, by distribution channel
7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific actinic keratosis treatment market, by type
7.4.5. Asia-Pacific actinic keratosis treatment market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil actinic keratosis treatment market, by drug type
7.5.2.1.2. Brazil actinic keratosis treatment market, by type
7.5.2.1.3. Brazil actinic keratosis treatment market, by distribution channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia actinic keratosis treatment market, by drug type
7.5.2.2.2. Saudi Arabia actinic keratosis treatment market, by type
7.5.2.2.3. Saudi Arabia actinic keratosis treatment market, by distribution channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa actinic keratosis treatment market, by drug type
7.5.2.3.2. South Africa actinic keratosis treatment market, by type
7.5.2.3.3. South Africa actinic keratosis treatment market, by distribution channel
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA actinic keratosis treatment market, by drug type
7.5.2.4.2. Rest of LAMEA actinic keratosis treatment market, by type
7.5.2.4.3. Rest of LAMEA actinic keratosis treatment market, by distribution channel
7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA actinic keratosis treatment market, by type
7.5.5. LAMEA actinic keratosis treatment market, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. 3M Company
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Almirall, S.A.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Bausch Health Companies Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Biofrontera, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. Hill Dermaceuticals, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. LEO Pharma A/S
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Mylan N.V
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Stanford Chemicals
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.)
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
